March 3, 2010 (FinancialWire) — Compugen (NASDAQ: CGEN) has appointed Anat Cohen-Dayag, Ph.D. as president and CEO, and Martin Gerstel as chairman. Previously, Cohen-Dayag and Gerstel served as co-CEOs of the company.

Prior to her appointment as co-CEO in June of last year, Cohen-Dayag, who joined Compugen in 2002, successively held the positions of director of diagnostics, vice president for diagnostic biomarkers & drug targets, and vice president of R&D.

Prior to joining Compugen, she was head of R&D and a member of the executive management at Mindsense Biosystems.

Gerstel joined Compugen in 1997 as chairman of the board, and served in that role until January last year when he was appointed president and CEO, and then co-CEO in June. Prior to joining Compugen he was co-chairman and CEO of Alza, a California-based pharmaceutical company which he helped found.

Dov Hershberg, who served as chairman of Compugen during 2009, will remain a director of the company.

Israel-based Compugen is a drug and diagnostic product candidate discovery company.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.